Low concentrations of mupirocin in the pharynx following intranasal application may contribute to mupirocin resistance in methicillin-resistant Staphylococcus aureus

被引:31
作者
Watanabe, H [1 ]
Masaki, H
Asoh, N
Watanabe, K
Oishi, K
Kobayashi, S
Sato, A
Sugita, R
Nagatake, T
机构
[1] Nagasaki Univ, Inst Trop Med, Dept Internal Med, Nagasaki 8528523, Japan
[2] Kyorin Hosp, Dept Internal Med, Nagasaki, Japan
[3] Kyorin Hosp, Dept Microbiol, Nagasaki, Japan
[4] Sugita Otorhinolaryngol Clin, Chiba, Japan
关键词
D O I
10.1128/JCM.39.10.3775-3777.2001
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
We describe a patient with methicillin-resistant Staphylococcus aureus (MRSA) colonizing the pharynx. The MIC of mupirocin was 0.25 mug/ml before treatment and increased after treatment to 8 mug/ml. Using pulsed-field gel electrophoresis, we confirmed that the genotypes of MRSA that colonized the pharynx before and after the use of mupirocin were identical. We measured the delivery of mupirocin to the pharynx in three normal volunteers and two patients. Low concentrations of mupirocin were present in the pharynx in all cases 10 min to 3 days after intranasal application. Our data suggested that low concentrations of the drug in the pharynx after intranasal application of mupirocin ointment might explain the selection of mupirocin resistance in MRSA.
引用
收藏
页码:3775 / 3777
页数:3
相关论文
共 19 条
  • [1] Molecular characterization and transfer among Staphylococcus strains of a plasmid conferring high-level resistance to mupirocin
    Bastos, MCF
    Mondino, PJJ
    Azevedo, MLB
    Santos, KRN
    Giambiagi-deMarval, M
    [J]. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1999, 18 (06) : 393 - 398
  • [2] MUPIROCIN-RESISTANT STAPHYLOCOCCUS-AUREUS
    COOKSON, BD
    LACEY, RW
    NOBLE, WC
    REEVES, DS
    WISE, R
    REDHEAD, RJ
    [J]. LANCET, 1990, 335 (8697) : 1095 - 1096
  • [3] Methicillin-resistant Staphylococcus aureus as a causative agent of postoperative intra-abdominal infection:: Relation to nasal colonization
    Fierobe, L
    Decré, D
    Mùller, C
    Lucet, JC
    Marmuse, JP
    Mantz, J
    Desmonts, JM
    [J]. CLINICAL INFECTIOUS DISEASES, 1999, 29 (05) : 1231 - 1238
  • [4] HIGH-LEVEL MUPIROCIN RESISTANCE IN STAPHYLOCOCCUS-AUREUS - EVIDENCE FOR 2 DISTINCT ISOLEUCYL-TRANSFER RNA-SYNTHETASES
    GILBART, J
    PERRY, CR
    SLOCOMBE, B
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (01) : 32 - 38
  • [5] Randomized, placebo-controlled, double-blind trial to evaluate the efficacy of mupirocin for eradicating carriage of methicillin-resistant Staphylococcus aureus
    Harbarth, S
    Dharan, S
    Liassine, N
    Herrault, P
    Auckenthaler, R
    Pittet, D
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (06) : 1412 - 1416
  • [6] ELIMINATION OF NASAL CARRIAGE OF METHICILLIN-RESISTANT STAPHYLOCOCCUS-AUREUS WITH MUPIROCIN DURING A HOSPITAL OUTBREAK
    HILL, RLR
    DUCKWORTH, GJ
    CASEWELL, MW
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1988, 22 (03) : 377 - 384
  • [7] Miller MA, 1996, INFECT CONT HOSP EP, V17, P811
  • [8] *NAT COMM CLIN LAB, 1998, M7A4 NAT COMM CLIN L
  • [9] National Committee for Clinical Laboratory Standards, 1998, M2A6 NAT COMM CLIN L
  • [10] NEU HC, 1990, INFECT CONT HOSP EP, V11, P11, DOI 10.1086/646071